![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HNRNPH1 |
Gene summary for HNRNPH1 |
![]() |
Gene information | Species | Human | Gene symbol | HNRNPH1 | Gene ID | 3187 |
Gene name | heterogeneous nuclear ribonucleoprotein H1 | |
Gene Alias | HNRPH | |
Cytomap | 5q35.3 | |
Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | P31943 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3187 | HNRNPH1 | C06 | Human | Oral cavity | OSCC | 5.98e-09 | 1.43e+00 | 0.2699 |
3187 | HNRNPH1 | C07 | Human | Oral cavity | OSCC | 2.58e-02 | 1.18e+00 | 0.2491 |
3187 | HNRNPH1 | C08 | Human | Oral cavity | OSCC | 1.20e-09 | 7.23e-01 | 0.1919 |
3187 | HNRNPH1 | C86 | Human | Oral cavity | OSCC | 3.48e-02 | 1.42e+00 | 0.161 |
3187 | HNRNPH1 | C09 | Human | Oral cavity | OSCC | 1.09e-07 | 7.42e-01 | 0.1431 |
3187 | HNRNPH1 | LN22 | Human | Oral cavity | OSCC | 3.35e-06 | 1.25e+00 | 0.1733 |
3187 | HNRNPH1 | LN38 | Human | Oral cavity | OSCC | 1.70e-10 | 1.33e+00 | 0.168 |
3187 | HNRNPH1 | LN46 | Human | Oral cavity | OSCC | 5.41e-05 | 9.98e-01 | 0.1666 |
3187 | HNRNPH1 | LP15 | Human | Oral cavity | LP | 2.30e-08 | 1.88e+00 | 0.2174 |
3187 | HNRNPH1 | LP17 | Human | Oral cavity | LP | 7.93e-09 | 1.59e+00 | 0.2349 |
3187 | HNRNPH1 | EOLP-1 | Human | Oral cavity | EOLP | 1.12e-11 | -1.08e-01 | -0.0202 |
3187 | HNRNPH1 | NEOLP-2 | Human | Oral cavity | NEOLP | 2.17e-02 | -4.41e-02 | -0.0196 |
3187 | HNRNPH1 | NEOLP-3 | Human | Oral cavity | NEOLP | 7.19e-06 | 2.49e-03 | -0.0191 |
3187 | HNRNPH1 | SYSMH1 | Human | Oral cavity | OSCC | 7.98e-07 | -7.18e-02 | 0.1127 |
3187 | HNRNPH1 | SYSMH2 | Human | Oral cavity | OSCC | 2.95e-13 | 8.31e-01 | 0.2326 |
3187 | HNRNPH1 | SYSMH3 | Human | Oral cavity | OSCC | 5.39e-21 | 8.07e-01 | 0.2442 |
3187 | HNRNPH1 | SYSMH4 | Human | Oral cavity | OSCC | 1.40e-09 | -1.14e-01 | 0.1226 |
3187 | HNRNPH1 | SYSMH6 | Human | Oral cavity | OSCC | 7.80e-05 | 4.86e-01 | 0.1275 |
3187 | HNRNPH1 | GSM5252127_BPH283PrSF_Via | Human | Prostate | BPH | 1.54e-05 | 7.03e-01 | -0.1453 |
3187 | HNRNPH1 | GSM5252129_BPH327PrSF_Via | Human | Prostate | BPH | 2.07e-03 | 5.95e-01 | -0.1697 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00083809 | Breast | Precancer | RNA splicing | 65/1080 | 434/18723 | 1.27e-12 | 2.53e-10 | 65 |
GO:00434849 | Breast | Precancer | regulation of RNA splicing | 34/1080 | 148/18723 | 2.66e-12 | 4.75e-10 | 34 |
GO:00003759 | Breast | Precancer | RNA splicing, via transesterification reactions | 52/1080 | 324/18723 | 1.74e-11 | 2.22e-09 | 52 |
GO:00003779 | Breast | Precancer | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:00003989 | Breast | Precancer | mRNA splicing, via spliceosome | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:000838014 | Breast | IDC | RNA splicing | 73/1434 | 434/18723 | 1.27e-10 | 1.57e-08 | 73 |
GO:004348414 | Breast | IDC | regulation of RNA splicing | 36/1434 | 148/18723 | 3.32e-10 | 3.77e-08 | 36 |
GO:000037514 | Breast | IDC | RNA splicing, via transesterification reactions | 58/1434 | 324/18723 | 9.44e-10 | 9.58e-08 | 58 |
GO:000037714 | Breast | IDC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 57/1434 | 320/18723 | 1.60e-09 | 1.49e-07 | 57 |
GO:000039814 | Breast | IDC | mRNA splicing, via spliceosome | 57/1434 | 320/18723 | 1.60e-09 | 1.49e-07 | 57 |
GO:000838024 | Breast | DCIS | RNA splicing | 73/1390 | 434/18723 | 3.05e-11 | 5.08e-09 | 73 |
GO:004348424 | Breast | DCIS | regulation of RNA splicing | 36/1390 | 148/18723 | 1.40e-10 | 1.69e-08 | 36 |
GO:000037524 | Breast | DCIS | RNA splicing, via transesterification reactions | 58/1390 | 324/18723 | 2.89e-10 | 3.34e-08 | 58 |
GO:000037724 | Breast | DCIS | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 57/1390 | 320/18723 | 5.01e-10 | 5.35e-08 | 57 |
GO:000039824 | Breast | DCIS | mRNA splicing, via spliceosome | 57/1390 | 320/18723 | 5.01e-10 | 5.35e-08 | 57 |
GO:004348410 | Cervix | CC | regulation of RNA splicing | 42/2311 | 148/18723 | 1.25e-07 | 6.24e-06 | 42 |
GO:000838010 | Cervix | CC | RNA splicing | 76/2311 | 434/18723 | 9.79e-04 | 8.19e-03 | 76 |
GO:000037710 | Cervix | CC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 55/2311 | 320/18723 | 6.71e-03 | 3.70e-02 | 55 |
GO:000039810 | Cervix | CC | mRNA splicing, via spliceosome | 55/2311 | 320/18723 | 6.71e-03 | 3.70e-02 | 55 |
GO:000037510 | Cervix | CC | RNA splicing, via transesterification reactions | 55/2311 | 324/18723 | 8.61e-03 | 4.44e-02 | 55 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HNRNPH1 | SNV | Missense_Mutation | c.1196N>A | p.Gly399Asp | p.G399D | P31943 | protein_coding | tolerated(0.06) | benign(0.188) | TCGA-C8-A135-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
HNRNPH1 | SNV | Missense_Mutation | novel | c.1114N>A | p.Tyr372Asn | p.Y372N | P31943 | protein_coding | tolerated(0.11) | benign(0) | TCGA-E2-A15O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | PD |
HNRNPH1 | insertion | Nonsense_Mutation | novel | c.1179_1180insCTCTGGCTTGGCAGTTGAGGCTGTTGCG | p.Ser394LeufsTer6 | p.S394Lfs*6 | P31943 | protein_coding | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | ||
HNRNPH1 | SNV | Missense_Mutation | c.617G>A | p.Arg206Gln | p.R206Q | P31943 | protein_coding | tolerated(0.09) | benign(0.014) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
HNRNPH1 | SNV | Missense_Mutation | novel | c.1327N>A | p.Asp443Asn | p.D443N | P31943 | protein_coding | tolerated_low_confidence(0.59) | benign(0) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
HNRNPH1 | SNV | Missense_Mutation | c.16G>A | p.Glu6Lys | p.E6K | P31943 | protein_coding | tolerated(0.06) | benign(0.024) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
HNRNPH1 | SNV | Missense_Mutation | novel | c.1103G>T | p.Ser368Ile | p.S368I | P31943 | protein_coding | deleterious(0.04) | benign(0.208) | TCGA-A6-A565-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unspecific | 5FU | PD |
HNRNPH1 | SNV | Missense_Mutation | c.616C>T | p.Arg206Trp | p.R206W | P31943 | protein_coding | tolerated(0.05) | benign(0.02) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
HNRNPH1 | SNV | Missense_Mutation | novel | c.211N>A | p.Leu71Met | p.L71M | P31943 | protein_coding | deleterious(0.01) | probably_damaging(0.961) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HNRNPH1 | SNV | Missense_Mutation | c.1188N>T | p.Met396Ile | p.M396I | P31943 | protein_coding | tolerated(0.69) | benign(0.104) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |